Accendra Health Faces NYSE Delisting After Trading Suspension
The NYSE suspended trading in Accendra Health common stock and began delisting proceedings, citing abnormally low selling prices. The company does not intend to appeal.
On November 16, 2026, Accendra Health received notice that the NYSE suspended trading in its common stock and commenced delisting proceedings, citing abnormally low selling prices under Section 802.01D of the NYSE Listed Company Manual. The company does not intend to appeal, and its stock began tra…